Navigation Links
European CHMP Adopts Negative Opinion on Cymbalta for the Treatment of Fibromyalgia
Date:10/24/2008

00 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine. In 2007, Boehringer Ingelheim posted net sales of 10.9 billion euro while spending one fifth of net sales in its largest business segment Prescription Medicines on research and development. For more information please visit http://www.boehringer-ingelheim.com.

Duloxetine for major depressive episodes, diabetic peripheral neuropathic pain and generalised anxiety disorder is marketed by Lilly and Boehringer Ingelheim in all countries included in the partnership under the brand name Cymbalta, except for Germany, Greece, Italy and Spain. In Germany, Lilly and Boehringer Ingelheim market duloxetine for major depressive episodes under the brand name Cymbalta, and market the product for diabetic peripheral neuropathic pain as Ariclaim(R). In Greece, Italy and Spain Lilly markets the product as Cymbalta and Boehringer Ingelheim markets the product as Xeristar(R). In the United States, Cymbalta is marketed by Lilly and Quintiles. In Japan, duloxetine is co-developed and co-marketed by Lilly and Shionogi & Co., Ltd.

Duloxetine for stress urinary incontinence is marketed by Lilly under the brand name Yentreve(R).

(1) Russell, IJ, et al. Efficacy and Safety of Duloxetine for Treatment of Fibromyalgia in Patients With or Without Major Depressive Disorder: Results From A Six-Month, Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Trial, Pain. 2008.

(2) Arnold, L, et al. A Randomized, Double-Blind, Placebo Controlled Trial of Duloxetine in the Treatment of Women with Fibromyalgia With or Without Major Depressive Disorder. Pain. 2005; 119 (1-3): 5-15

(3) Arnold, L, et al. A Double-Blind, Multicenter Trial Comparing Duloxetine with Placebo in the Treatment of Fi
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
2. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
3. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
4. Kline Study: Better Brushing Habits Boost European Oral Care Sales
5. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
6. European Centre for Modern Drug Discovery Established in Hamburg
7. SAFC Expands European Commercial Manufacturing and Storage Capacities With $10 Million Investment
8. Cardica Receives European CE Mark for C-Port Flex A System for Use in Coronary Artery Bypass Surgery
9. Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting
10. Intellect Neurosciences, Inc. Obtains Validation of European Patent for Alzheimers Vaccine in 19 Countries
11. Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Hodgkins Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the ... venture with G-treeBNT (ReGenTree LLC) has retained Ora, ... for the orphan disorder, neurotrophic keratopathy (NK), and ... syndrome (DES) in the U.S.  Both trials will ... year.  Each of these eye disorders was being ...
(Date:4/16/2015)... A new infographic compiles useful information about Research ... learn how Apple’s new framework can change the way ... since Apple made Research Kit available to ... for developing medical research apps that Apple announced on ... collect secure clinical data and communicate via subjects’ smartphones. ...
(Date:4/16/2015)... , April 16, 2015 Avelas Biosciences, an ... improving cancer surgeries, announced today that it has initiated ... illuminator, AVB-620, in women with primary, non-recurrent breast cancer ... also welcomed the addition of Steven Chen , ... The open label, dose escalation study will enroll up ...
(Date:4/16/2015)... and MENLO PARK, Calif. ... (OTCQX: DMPI) (DelMar and the Company), a biopharmaceutical ... in new orphan drug indications, today announced that the ... as a clinical trial site for the ongoing, multicenter ... glioblastoma multiforme (GBM), the most common and deadly form ...
Breaking Biology Technology:RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5Infographic Illustrates Potential for Research Kit to Impact Clinical Research 2Infographic Illustrates Potential for Research Kit to Impact Clinical Research 3Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 2DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 4DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 5
... , , , For automated purification of genomic and mitochondrial , DNA from ... Format: , 96-well plates (for ... QIAamp DNA Blood MDX Protocol, , , ... blood (with common anticoagulants , such as citrate and EDTA) , ...
... , , , , , For , HotStarTaq DNA Polymerase , ... , , , ... Storage and Stability , Technical Assistance , ... , , , ...
... , , , , Andreas Pahl, ... Department of Pharmacology, University of Erlangen, Erlangen, Germany , ... , , , , Drug library screening ... of RNA purification , and sensitive, quantitative, real-time RT-PCR analysis. This ...
Cached Biology Technology:QIAamp DNA Blood BioRobot MDx Kit 2HotStarTaq PCR Handbook 2HotStarTaq PCR Handbook 3HotStarTaq PCR Handbook 4HotStarTaq PCR Handbook 5HotStarTaq PCR Handbook 6HotStarTaq PCR Handbook 7HotStarTaq PCR Handbook 8HotStarTaq PCR Handbook 9HotStarTaq PCR Handbook 10HotStarTaq PCR Handbook 11HotStarTaq PCR Handbook 12HotStarTaq PCR Handbook 13HotStarTaq PCR Handbook 14HotStarTaq PCR Handbook 15HotStarTaq PCR Handbook 16HotStarTaq PCR Handbook 17HotStarTaq PCR Handbook 18HotStarTaq PCR Handbook 19HotStarTaq PCR Handbook 20HotStarTaq PCR Handbook 21HotStarTaq PCR Handbook 22HotStarTaq PCR Handbook 23HotStarTaq PCR Handbook 24HotStarTaq PCR Handbook 25HotStarTaq PCR Handbook 26HotStarTaq PCR Handbook 27HotStarTaq PCR Handbook 28HotStarTaq PCR Handbook 29HotStarTaq PCR Handbook 30HotStarTaq PCR Handbook 31HotStarTaq PCR Handbook 32HotStarTaq PCR Handbook 33High-throughput gene expression analysis to screen for anti-asthma drugs 2High-throughput gene expression analysis to screen for anti-asthma drugs 3
(Date:3/24/2015)... Research and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ) ... Recognition Market 2015-2019" report to their offering. ... to grow at a CAGR of 23.5 percent over ... present scenario and the growth prospects of the Global ... the market size, the report considers the revenue generated ...
(Date:3/23/2015)... , March 23, 2015 SoundView Technology Group issues ... (NASDAQ: NXTD ) Wocket smart wallet. SoundView was one of ... on their experience with the Wocket in multiple scenarios and ... Whole Foods and other retailers, making both debit and credit ... also says, "If the company meets their plans in ...
(Date:3/20/2015)... , Mar. 20, 2015 Research and ... the addition of the "India Sensors Market ... offering. The sensor market is projected ... 2020 Consumer electronics, automotive, industrial and ... sensors in the country. In addition, adoption of ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3
... Biologists have learned where and how some plant seeds store ... iron content of plants. Their research helps address the worldwide ... team found that iron is stored in the developing vascular ... in research. In particular, iron is stored in the vacuole, ...
... Genomic technologies may have the potential to alleviate ... Researchers believe that biotechnology has the potential to ... crucially, resistance to insects and disease. This could ... both human and animal consumption. Researchers are ...
... team at the Consejo Superior de Investigaciones Científicas (CSIC) ... proteins in plant cells, a discovery that will enable ... these can be used to produce oral vaccines which, ... diseases. Moreover, this discovery opens the door to the ...
Cached Biology News:Plant studies reveal how, where seeds store iron 2Are genomic technologies the answer to world hunger? 2Vaccine-producing 'plant-factories' 2